29 July 2025

Moray & Agnew Lawyers has advised GPN Vaccines Ltd (GPN Vaccines) on its successful re-domiciliation from Australia to the United States of America (USA) by way of a scheme of arrangement.

GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world’s most important bacterial pathogens. These pathogens are responsible for causing a wide range of illnesses from middle ear infections to life-threatening pneumonia.

The re-domiciliation to the USA will position GPN Vaccines to broaden its reach into the world’s largest healthcare market, expand engagement with leading investors and industry partners and allow the company to accelerate delivery of innovative therapies through the clinic and to patients worldwide.

Phillip Grundy, Partner and Head of the Corporate team commented, “It has been a pleasure advising GPN Vaccines on its successful re-domiciliation to the USA, providing the company with the opportunity to advance its clinical trials and regulatory pathways with the FDA and have greater access to the strong biotech capital markets in the USA.”